You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Mallinckrodt
Medtronic
McKesson

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYOBLOC

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for MYOBLOC

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed ALS Association Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed University of Kansas Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00125203 Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed The University of Texas Health Science Center at San Antonio Phase 2/Phase 3 2003-07-01 The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling. The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.
NCT00208091 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed Solstice Neurosciences Phase 4 2003-04-01 This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.
NCT00208091 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed Columbia University Phase 4 2003-04-01 This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MYOBLOC

Condition Name

Condition Name for MYOBLOC
Intervention Trials
Sialorrhea 3
Low Back Pain 2
Stroke 2
Spinal Cord Injury (SCI) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for MYOBLOC
Intervention Trials
Sialorrhea 3
Muscle Spasticity 3
Back Pain 2
Low Back Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for MYOBLOC

Trials by Country

Trials by Country for MYOBLOC
Location Trials
United States 42
Russian Federation 4
Ukraine 2
Belarus 1
Lebanon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for MYOBLOC
Location Trials
Maryland 3
California 3
New York 3
District of Columbia 3
New Jersey 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for MYOBLOC

Clinical Trial Phase

Clinical Trial Phase for MYOBLOC
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
Phase 2/Phase 3 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for MYOBLOC
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for MYOBLOC

Sponsor Name

Sponsor Name for MYOBLOC
Sponsor Trials
US WorldMeds LLC 3
Solstice Neurosciences 2
Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for MYOBLOC
Sponsor Trials
Other 10
Industry 6
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.